Entries by Max

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

/in , /by

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

/in , /by

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

PT-112 Update: Phase 2 Biomarker Findings Pave Way for Phase 3 in End-Stage Prostate Cancer

/in , , /by

Since FDA cleared PT-112 for a pivotal phase 3 trial in May 2025 (we talked about it here) following a successful end-of-phase-2 meeting, fresh insights illuminate why this novel platinum-based agent merits excitement for late-line metastatic castration-resistant prostate cancer (mCRPC). PT-112 stands apart from traditional platinums: its pyrophosphate structure drives osteotropism (high bone accumulation alongside […]

Dual FOXA1/FOXA2 Targeting to Shut Down Lineage-Plastic Castration-Resistant Prostate Cancer

/in /by

Targeting FOXA1 and FOXA2 in castration-resistant prostate cancer represents a new way of attacking the disease at the level of its lineage “identity” rather than only at the androgen receptor. FOXA1 and FOXA2 belong to a family of pioneer transcription factors. These pioneer transcription factors unlock tightly packed DNA, creating access for other proteins that […]

Newsletter 1/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Here I am again! The first newsletter of 2026. It’s particularly rich in preclinical research, just to get a sense of where we’re heading in the near future. Stay strong and fight on! As usual, we also have a podcast […]

KAIST In Situ CAR-Macrophage Therapy

/in , /by

The KAIST team has introduced a highly innovative form of cancer immunotherapy that turns the body’s own macrophages into potent, targeted cancer killers directly inside solid tumours. Instead of the classic, laborious route of extracting immune cells from a patient, engineering them in a lab, expanding them, and reinfusing them, this approach reprograms macrophages already […]

From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines

/in , /by

A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]

HRS-4357, a Novel PSMA-targeted Radiologand Therapy Phase 3 Trial

/in , , /by

HRS-4357, a novel PSMA-targeted radiopharmaceutical, is poised to enter a landmark Phase III clinical trial targeting metastatic castration-resistant prostate cancer (mCRPC). The trial, received approval from China’s National Medical Products Administration on December 23, 2025, and plans to enroll 370 patients across multiple centers in China. This randomized, open-label, controlled study will directly compare HRS-4357 […]

Dapagliflozin and Next-Generation Hormonal Agents: Targeting Metabolic Resistance in Metastatic Castrate-Resistant Prostate Cancer

/in , , /by

A new phase 2 clinical trial is now underway to test whether adding dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, to next-generation hormonal agents (darolutamide, abiraterone, apalutamide, enzalutamide) can extend survival in metastatic castrate-resistant prostate cancer. The rationale rests on a fundamental paradox in prostate cancer biology: while early tumors rely on oxidative metabolism and androgen signaling, […]